Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SAN DIEGO, Feb. 08, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference in New York City on Wednesday, February 15, 2017 at 10:00 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
